TARDBP and Alzheimer disease: The sensitivity of clinical findings for predicting underlying CBDpathology ranges from 26% to 56 %.45-47 Lee et al. (2011)observed a 35% prevalence of CBD post-mortem in 40 patients meeting CBS criteria,followed by 23% AD, 13% PSP and 13% FTLD-TDP43.8